| abstract |
Provided herein are formulations and solid crystal and amorphous forms and methods of use relating to 1-ethyl-7- (2-methyl- 6-(1H- 1,2,4-triazol -3-yl)pyridin-3-yl)-3,4-dihydropyrazino(2,3-b ]pyrazin-2(1 H)-one. Characterization by X-ray powder diffraction and thermal analysis of the solvate and hydrates of the isolated crystal forms are also disclosed. The solid forms provided herein can be used in methods for treating or preventing cancer, an inflammatory condition, an immunological condition, a neurodegenerative disease, diabetes, obesity, a neurological disorder, an age-related disease, a cardiovascular condition, or a conditions treatable or preventable by inhibition of a kinase pathway. The methods comprise administering an effective amount of a crystal form provided herein to a subject in need thereof. |